YMAB - Y-mAbs Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.79
-0.26 (-1.13%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close23.05
Open23.18
Bid21.78 x 800
Ask25.91 x 800
Day's Range21.81 - 23.18
52 Week Range15.17 - 31.00
Volume28,805
Avg. Volume103,693
Market Cap779.274M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.46
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Trade prices are not sourced from all markets
  • What Kind Of Investor Owns Most Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)?
    Simply Wall St.last month

    What Kind Of Investor Owns Most Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)?

    A look at the shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...

  • GlobeNewswirelast month

    Y-mAbs Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Dec. 13, 2018 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswirelast month

    Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the appointment of the molecular nuclear medicine executive, Dr. Gérard Ber, PhD to its board of directors, and the planned departure of Dr. Michael Buschle, PhD. The departure of Dr. Buschle and the appointment of Dr. Ber is effective December 11, 2018.

  • GlobeNewswirelast month

    Y-mAbs Therapeutics Announces FDA Clearance of IND for its Bispecific GD2 Antibody

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Investigational New Drug (“IND”) application for a humanized bispecific GD2 antibody. It is anticipated that a Phase 1/2 clinical trial will soon be initiated to begin screening patients with relapsed/refractory neuroblastoma, high grade osteosarcoma and other GD2(+) solid tumors, where patients have relapsed or refractory disease that is resistant to standard therapy.

  • GlobeNewswire3 months ago

    Bispecific GD2 Antibody In Vivo Data to be Presented at ASH

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Jeong A Park from the Department of Pediatrics of Memorial Sloan-Kettering Cancer Center (MSK) will present preclinical data from the Company’s bispecific GD2 antibody in a poster presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA on December 3, 2018, at 9:00 PM Eastern. Bispecific GD2 antibodies were tested in solid tumors in preclinical models with T-cells and were shown to exert anti-tumor effect against GD2(+) tumor xenografts or PDX tumors.

  • GlobeNewswire3 months ago

    Naxitamab Receives Positive Opinion for Orphan Medicinal Product Designation Approval in the EU

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) today announced that the Committee for Orphan Medicinal Products (“COMP”) of the European Medicines Agency (“EMA”) has recommended the granting of orphan medicinal product designation (“OMPD”) in the European Union (“EU”) for naxitamab, one of the Company’s lead product candidates, for the treatment of relapsed or refractory high-risk neuroblastoma. The positive opinion from the EMA's COMP has been sent to the European Commission (“EC”), which is expected to grant the orphan drug designation within 30 days.